NCT03699553已完成不适用
Positive Affect Regulation as Adjuvant to Integrative Therapies for Chronic Pain: Development of the LARKSPUR Clinic-Based Intervention
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 80
- 试验地点
- 2
- 主要终点
- Retention to the LARKSPUR Study from baseline to 12 weeks post baseline
研究概览
简要总结
Chronic pain affects millions of Americans but integrative as well as conventional treatments fall short in terms of alleviating this pain. The investigators are testing a tailored online positive affect skills intervention through a high-quality, randomized controlled trial for people with chronic musculoskeletal pain. The proposed work holds promise as an effective, low cost, easily disseminated intervention to help people cope with chronic pain, decrease depression and distress that pose barriers to optimal adherence, and potentially boost the efficacy of integrative as well as conventional pain treatments.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age 18 and over
- •Current patient at Northwestern Memorial Hospital
- •Seeking treatment for chronic musculoskeletal pain at the Northwestern Osher Center for Integrative Medicine. Pain will be defined as persisting for at least the past three months with an average level over the past month of at least 4 of 10 on a numerical rating scale, including back pain, neck pain/cervicalgia, knee pain, other joint pain (hips, ankles), fibromyalgia, osteoarthritis and rheumatoid arthritis.
- •Fluent in the English language
- •Have a working email address
- •Have reliable Internet access in order to access the website online
排除标准
- 未提供
结局指标
主要结局
Retention to the LARKSPUR Study from baseline to 12 weeks post baseline
时间窗: 12 weeks; from baseline to 12 weeks post baseline
Retention will be defined as responding to the assessments at baseline and at 12 weeks post baseline
Retention to the LARKSPUR Study from baseline to 8 weeks post baseline
时间窗: 8 weeks; from baseline to 8 weeks post baseline
Retention will be defined as responding to the assessments at baseline and at 8 weeks post baseline
次要结局
- Modified Differential Emotions Scale (mDES)(Administered daily for 5 weeks of the intervention period)
- Daily Inventory of Stressful Events (DISE)(Administered daily for 5 weeks of the intervention period)
- Self-Reported Medication use at 8 weeks post baseline(Administered at 8 weeks post baseline)
- Pain Level, measured by a single-item pain question(Administered daily for 5 weeks of the intervention period)
- Emotional Support at baseline using the NIH Toolbox for Emotional Support(Administered at baseline)
- Pain on average over 7 days at 8 weeks post baseline through a single-item question(Administered at 8 weeks post baseline)
- Depression at 12 weeks post baseline using the PROMIS measure(Administered at 12 weeks post baseline)
- Emotional Support at 12 weeks post baseline using the NIH Toolbox for Emotional Support(Administered at 12 weeks post baseline)
- Physical Function at Baseline through the PROMIS measure for physical function(Administered at baseline)
- Physical Function at 12 weeks post baseline through the PROMIS measure for physical function(Administered at 12 weeks post baseline)
- Depression at baseline using the PROMIS measure(Administered at baseline)
- Depression at 8 weeks post baseline using the PROMIS measure(Administered at 8 weeks post baseline)
- Pain Intensity at 8 weeks post baseline using the PROMIS measure(Administered at 8 weeks post baseline)
- Pain Intensity at 12 weeks post baseline using the PROMIS measure(Administered at 12 weeks post baseline)
- Pain Self Efficacy at baseline (PSEQ)(Administered at baseline)
- Pain Self Efficacy at 12 weeks post baseline (PSEQ)(Administered at 12 weeks post baseline)
- Pain catastrophizing at 12 weeks post baseline(Administered at 12 weeks post baseline)
- Self-Reported Medication use at baseline(Administered at baseline)
- Self-Reported Medication use at 12 weeks post baseline(Administered at 12 weeks post baseline)
- Pain on average over 7 days at baseline through a single-item question(Administered at baseline)
- Pain resilience at 8 weeks post baseline(Administered at 8 weeks post baseline)
- Pain resilience at 12 weeks post baseline(Administered at 12 weeks post baseline)
- Sleep disturbance at baseline using the PROMIS measure(Administered at baseline)
- Sleep disturbance at 8 weeks post baseline using the PROMIS measure(Administered at 8 weeks post baseline)
- Positive Affect using the NIH Toolbox for Positive Affect, Short-Form (Baseline)(Administered at baseline)
- Positive Affect using the NIH Toolbox for Positive Affect, Short-Form (8 weeks post baseline)(Administered at 8 weeks post baseline)
- Positive Affect using the NIH Toolbox for Positive Affect, Short-Form (12 weeks post baseline)(Administered at 12 weeks post baseline)
- Emotional Support at 8 weeks post baseline using the NIH Toolbox for Emotional Support(Administered at 8 weeks post baseline)
- Physical Function at 8 weeks post baseline through the PROMIS measure for physical function(Administered at 8 weeks post baseline)
- Pain on average over 7 days at 12 weeks post baseline through a single-item question(Administered at 12 weeks post baseline)
- Pain interference at 8 weeks post baseline using the PROMIS measure(Administered at 8 weeks post baseline)
- Pain interference at 12 weeks post baseline using the PROMIS measure(Administered at 12 weeks post baseline)
- Pain Self Efficacy at 8 weeks post baseline (PSEQ)(Administered at 8 weeks post baseline)
- Patient adherence at baseline(Administered at baseline)
- Patient adherence at 8 weeks post baseline(Administered at 8 weeks post baseline)
- Anxiety at baseline using the PROMIS measure(Administered at baseline)
- Anxiety at 12 weeks post baseline using the PROMIS measure(Administered at 12 weeks post baseline)
- Pain Intensity at baseline using the PROMIS measure(Administered at baseline)
- Pain interference at baseline using the PROMIS measure(Administered at baseline)
- Pain catastrophizing at 8 weeks post baseline(Administered at 8 weeks post baseline)
- Anxiety at 8 weeks post baseline using the PROMIS measure(Administered at 8 weeks post baseline)
- Pain resilience at baseline(Administered at baseline)
- Pain catastrophizing at baseline(Administered at baseline)
- Sleep disturbance at 12 weeks post baseline using the PROMIS measure(Administered at 12 weeks post baseline)
- Patient adherence at 12 weeks post baseline(Administered at 12 weeks post baseline)
研究者
Judith Moskowitz
Professor
Northwestern University
研究点 (2)
Loading locations...
相似试验
Enrolling By Invitation
不适用
MAGIC Study: More Access to Group Integrative CareChronic PainNCT06228755University of North Carolina, Chapel Hill70
进行中（未招募）
不适用
The Effect of Light Therapy on Chronic PainChronic PainNCT03677206University of Arizona55
已完成
不适用
Back on Track to Healthy Living StudyChronic PainNCT03687762University of Washington397
已完成
早期 1 期
Developing Brain Stimulation as a Treatment for Chronic Pain in Opiate DependentChronic PainOpiate DependenceLower Back PainNCT03681769Medical University of South Carolina24
已完成
不适用
Project Relief: Developing Brain Stimulation as a Treatment for Chronic PainChronic PainChronic Lower Back PainBack PainOpioid UseOpiate DependencePain, ChronicNeuropathic PainChemotherapy-induced Peripheral NeuropathyNCT04156802Wake Forest University Health Sciences38